TheraGenetics Bought by Avacta
Luke Timmerman1/29/09
TheraGenetics, a Cambridge, MA and London-based diagnostics company, said today it agreed to be acquired by UK-based Avacta Group for an undisclosed amount of cash and stock. TheraGenetics is developing diagnostic tests to see how individual patients might respond to drugs for schizophrenia, depression, bipolar disorder, Alzheimer’s disease and attention deficit hyperactivity disorder.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
Who’s Getting Paid: The Week in Deals | IguanaBio - A Daily Biotech and Pharma Tabloid - Gossip, News, Humor and Updates on the Latest Events in the Biotechnology and Pharmaceutical Industries
2/2/09 1:50 pm
[...] Theragenetics is another not-so-well know company that develops diagnostic tests for various CNS diseases. The company announced back in January that contract service provider Avacta would be acquiring them for $2.9M. Peanuts. [Xconomy] [...]